SIGHT.PA Live signaler | Maksimer profitt med Getagraph.com

Live Chart Being Loaded With Signals

Commentary (29 apr 2024 @ 13:57):

Stats
Dagens volum	79 006.00
Gjennomsnittsvolum	152 046
Markedsverdi	31.99M
EPS	€0 ( 2024-03-26 )
Neste inntjeningsdato	( €0 ) 2024-05-29
Last Dividend	€0 ( N/A )
Next Dividend	€0 ( N/A )
P/E	-0.760
ATR14	€0.00300 (0.73%)

Gensight Biologics SA Korrelasjon

10 Mest positive korrelasjoner

10 Mest negative korrelasjoner

Visste du det?

Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).

Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.

Gensight Biologics SA Økonomi

Annual	2023
Omsetning:	€1.27M
Bruttogevinst:	€3.00M (236.78 %)
EPS:	€-0.540

FY	2023
Omsetning:	€1.27M
Bruttogevinst:	€3.00M (236.78 %)
EPS:	€-0.540

FY	2022
Omsetning:	€2.58M
Bruttogevinst:	€2.58M (100.00 %)
EPS:	€-0.600

FY	2021
Omsetning:	€5.28M
Bruttogevinst:	€0.00 (0.00 %)
EPS:	€-0.630

Financial Reports:

No articles found.

Gensight Biologics SA

GenSight Biologics S.A., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies for mitochondrial and neurodegenerative diseases of the eye and central nervous system. The company develops its products through gene therapy-based mitochondrial targeting sequence and optogenetics technology platforms. Its lead product candidates include LUMEVOQ (GS010), a recombinant AAV2-based gene therapy, which is in Phase III clinical trials for the treatment of leber hereditary optic neuropathy caused by a mutated ND4 gene; and GS030, which is in Phase I/II clinical trial for the treatment of retinitis pigmentosa, as well as in preclinical stage to treat dry age-related macular degeneration. The company also develops products that are in preclinical stage targeting ophthalmic and neurodegenerative diseases. GenSight Biologics S.A. was incorporated in 2012 and is headquartered in Paris, France.